B. Riley Securities Maintains Buy on Immunic, Lowers Price Target to $27
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
B. Riley Securities analyst William Woods maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $27.
B. Riley Securities analyst William Woods maintains Immunic (NASDAQ:IMUX) with a Buy and lowers the price target from $40 to $27.